Profile

The Coffey lab seeks a comprehensive understanding of the role of EGF receptor (EGFR) and its ligands in epithelial cell growth, differentiation and neoplasia.  In vitro, we study spatial compartmentalization of key components of the EGFR axis in the context of polarized epithelial cells.  For example, two critical EGFR ligands, TGF-alpha and amphiregulin, are both delivered exclusively to the basolateral surface, cleaved by TACE/ADAM-17, but then interact with basolateral EGFRs in very different ways.  Naked2 and MAGI-3 have been identified recently as two proteins that bind the cytoplasmic tail of TGF-alpha and play important roles in the fidelity (former) and efficiency (latter) of TGF-alphas trafficking to the basolateral surface.  Naked2 coats exocytic vesicles that contain TGF-alpha and escorts these vesicles to the basolateral surface where they dock and fuse in a Naked2 myristoylation-dependent manner.  Naked2 vesicles have been isolated, 389 proteins have been identified by use of fluorescence-activated vesicle sorting (FAVS) and LC/MS-MS.

In vivo, mouse models of GI neoplasia are being developed and utilized by Vanderbilt's involvement in the NCI-sponsored Mouse Models of Human Cancers Consortium (of which Dr. Coffey is PI).  Innovative therapeutic strategies to disrupt the EGFR axis (ligand cleavage, ligand uptake by receptor, receptor tyrosine kinase activity) in GI neoplasia are fashioned in tissue culture models, refined in mouse models and advanced to clinical trials.  A recent example is the successful treatment of a patient with a premalignant disorder of the stomach, Menetrier's disease with EGFR blockade (Erbitux).  These efforts have been greatly accelerated by Vanderbilt receiving a 5-year, $13 million GI Special Program of Research Excellence (SPORE) award from the NCI to study colorectal cancer; Dr. Coffey is PI.  A major effort is to identify the colonic stem cell using microarray and proteomic profiling.  Dr. Coffey also directs the recently-formed VUMC Epithelial Biology Center.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. KRAS-MEK Signaling Controls Ago2 Sorting into Exosomes. McKenzie AJ, Hoshino D, Hong NH, Cha DJ, Franklin JL, Coffey RJ, Patton JG, Weaver AM (2016) Cell Rep 15(5): 978-87
    › Primary publication · 27117408 (PubMed) · PMC4857875 (PubMed Central)
  2. Differences in severity at admission for heart failure between rural and urban patients: the value of adding laboratory results to administrative data. Smith MW, Owens PL, Andrews RM, Steiner CA, Coffey RM, Skinner HG, Miyamura J, Popescu I (2016) BMC Health Serv Res : 133
    › Primary publication · 27089888 (PubMed) · PMC4836154 (PubMed Central)
  3. Ubiquilin-mediated Small Molecule Inhibition of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling. Coffey RT, Shi Y, Long MJ, Marr MT, Hedstrom L (2016) J Biol Chem 291(10): 5221-33
    › Primary publication · 26740621 (PubMed) · PMC4777855 (PubMed Central)
  4. Ménétrier's Disease: Its Mimickers and Pathogenesis. Huh WJ, Coffey RJ, Washington MK (2016) J Pathol Transl Med 50(1): 10-6
    › Primary publication · 26689786 (PubMed) · PMC4734964 (PubMed Central)
  5. p120-catenin controls contractility along the vertical axis of epithelial lateral membranes. Yu HH, Dohn MR, Markham NO, Coffey RJ, Reynolds AB (2016) J Cell Sci 129(1): 80-94
    › Primary publication · 26585313 (PubMed) · PMC4732297 (PubMed Central)
  6. Cytometry-based single-cell analysis of intact epithelial signaling reveals MAPK activation divergent from TNF-α-induced apoptosis in vivo. Simmons AJ, Banerjee A, McKinley ET, Scurrah CR, Herring CA, Gewin LS, Masuzaki R, Karp SJ, Franklin JL, Gerdes MJ, Irish JM, Coffey RJ, Lau KS (2015) Mol Syst Biol 11(10): 835
    › Primary publication · 26519361 (PubMed) · PMC4631206 (PubMed Central)
  7. Potential functional applications of extracellular vesicles: a report by the NIH Common Fund Extracellular RNA Communication Consortium. Quesenberry PJ, Aliotta J, Camussi G, Abdel-Mageed AB, Wen S, Goldberg L, Zhang HG, Tetta C, Franklin J, Coffey RJ, Danielson K, Subramanya V, Ghiran I, Das S, Chen CC, Pusic KM, Pusic AD, Chatterjee D, Kraig RP, Balaj L, Dooner M (2015) J Extracell Vesicles : 27575
    › Primary publication · 26320942 (PubMed) · PMC4553260 (PubMed Central)
  8. Induction of lateral lumens through disruption of a monoleucine-based basolateral-sorting motif in betacellulin. Singh B, Bogatcheva G, Starchenko A, Sinnaeve J, Lapierre LA, Williams JA, Goldenring JR, Coffey RJ (2015) J Cell Sci 128(18): 3444-55
    › Primary publication · 26272915 (PubMed) · PMC4582402 (PubMed Central)
  9. LRIG1 Regulates Ontogeny of Smooth Muscle-Derived Subsets of Interstitial Cells of Cajal in Mice. Kondo J, Powell AE, Wang Y, Musser MA, Southard-Smith EM, Franklin JL, Coffey RJ (2015) Gastroenterology 149(2): 407-19.e8
    › Primary publication · 25921371 (PubMed) · PMC4527342 (PubMed Central)
  10. [(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study. McKinley ET, Watchmaker JM, Chakravarthy AB, Meyerhardt JA, Engelman JA, Walker RC, Washington MK, Coffey RJ, Manning HC (2015) Ann Nucl Med 29(6): 535-42
    › Primary publication · 25899481 (PubMed) · PMC4503488 (PubMed Central)
  11. Loss of Lrig1 leads to expansion of Brunner glands followed by duodenal adenomas with gastric metaplasia. Wang Y, Shi C, Lu Y, Poulin EJ, Franklin JL, Coffey RJ (2015) Am J Pathol 185(4): 1123-34
    › Primary publication · 25794708 (PubMed) · PMC4380843 (PubMed Central)
  12. Using a new Lrig1 reporter mouse to assess differences between two Lrig1 antibodies in the intestine. Poulin EJ, Powell AE, Wang Y, Li Y, Franklin JL, Coffey RJ (2014) Stem Cell Res 13(3 Pt A): 422-30
    › Primary publication · 25460603 (PubMed) · PMC4320017 (PubMed Central)
  13. 3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer. McKinley ET, Zhao P, Coffey RJ, Washington MK, Manning HC (2014) PLoS One 9(9): e108193
    › Primary publication · 25247710 (PubMed) · PMC4172755 (PubMed Central)
  14. Proteogenomic characterization of human colon and rectal cancer. Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z, Chambers MC, Zimmerman LJ, Shaddox KF, Kim S, Davies SR, Wang S, Wang P, Kinsinger CR, Rivers RC, Rodriguez H, Townsend RR, Ellis MJ, Carr SA, Tabb DL, Coffey RJ, Slebos RJ, Liebler DC, NCI CPTAC (2014) Nature 513(7518): 382-7
    › Primary publication · 25043054 (PubMed) · PMC4249766 (PubMed Central)
  15. DIPA-family coiled-coils bind conserved isoform-specific head domain of p120-catenin family: potential roles in hydrocephalus and heterotopia. Markham NO, Doll CA, Dohn MR, Miller RK, Yu H, Coffey RJ, McCrea PD, Gamse JT, Reynolds AB (2014) Mol Biol Cell 25(17): 2592-603
    › Primary publication · 25009281 (PubMed) · PMC4148249 (PubMed Central)
  16. Inducible loss of one Apc allele in Lrig1-expressing progenitor cells results in multiple distal colonic tumors with features of familial adenomatous polyposis. Powell AE, Vlacich G, Zhao ZY, McKinley ET, Washington MK, Manning HC, Coffey RJ (2014) Am J Physiol Gastrointest Liver Physiol 307(1): G16-23
    › Primary publication · 24833705 (PubMed) · PMC4080164 (PubMed Central)
  17. Genetic variants of Adam17 differentially regulate TGFβ signaling to modify vascular pathology in mice and humans. Kawasaki K, Freimuth J, Meyer DS, Lee MM, Tochimoto-Okamoto A, Benzinou M, Clermont FF, Wu G, Roy R, Letteboer TG, Ploos van Amstel JK, Giraud S, Dupuis-Girod S, Lesca G, Westermann CJ, Coffey RJ, Akhurst RJ (2014) Proc Natl Acad Sci U S A 111(21): 7723-8
    › Primary publication · 24812125 (PubMed) · PMC4040598 (PubMed Central)
  18. Excess PLAC8 promotes an unconventional ERK2-dependent EMT in colon cancer. Li C, Ma H, Wang Y, Cao Z, Graves-Deal R, Powell AE, Starchenko A, Ayers GD, Washington MK, Kamath V, Desai K, Gerdes MJ, Solnica-Krezel L, Coffey RJ (2014) J Clin Invest 124(5): 2172-87
    › Primary publication · 24691442 (PubMed) · PMC4001536 (PubMed Central)
  19. From wavy hair to naked proteins: the role of transforming growth factor alpha in health and disease. Singh B, Coffey RJ (2014) Semin Cell Dev Biol : 12-21
    › Primary publication · 24631356 (PubMed) · PMC4105142 (PubMed Central)
  20. A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells. Hight MR, Cheung YY, Nickels ML, Dawson ES, Zhao P, Saleh S, Buck JR, Tang D, Washington MK, Coffey RJ, Manning HC (2014) Clin Cancer Res 20(8): 2126-35
    › Primary publication · 24573549 (PubMed) · PMC3989451 (PubMed Central)
  21. NEDD4L is downregulated in colorectal cancer and inhibits canonical WNT signaling. Tanksley JP, Chen X, Coffey RJ (2013) PLoS One 8(11): e81514
    › Primary publication · 24312311 (PubMed) · PMC3842946 (PubMed Central)
  22. Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer. McKinley ET, Liu H, McDonald WH, Luo W, Zhao P, Coffey RJ, Hanks SK, Manning HC (2013) PLoS One 8(11): e80207
    › Primary publication · 24260357 (PubMed) · PMC3832668 (PubMed Central)
  23. Deciphering genomic alterations in colorectal cancer through transcriptional subtype-based network analysis. Zhu J, Wang J, Shi Z, Franklin JL, Deane NG, Coffey RJ, Beauchamp RD, Zhang B (2013) PLoS One 8(11): e79282
    › Primary publication · 24260186 (PubMed) · PMC3829853 (PubMed Central)
  24. LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. Wang Y, Poulin EJ, Coffey RJ (2013) Br J Cancer 108(9): 1765-70
    › Primary publication · 23558895 (PubMed) · PMC3658528 (PubMed Central)
  25. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, Higginbotham JN, Juchheim A, Prasad N, Levy SE, Guo Y, Shyr Y, Aronow BJ, Haigis KM, Franklin JL, Coffey RJ (2012) Cell 149(1): 146-58
    › Primary publication · 22464327 (PubMed) · PMC3563328 (PubMed Central)
  26. Gastric tumor development in Smad3-deficient mice initiates from forestomach/glandular transition zone along the lesser curvature. Nam KT, O'Neal R, Lee YS, Lee YC, Coffey RJ, Goldenring JR (2012) Lab Invest 92(6): 883-95
    › Primary publication · 22411066 (PubMed) · PMC3584162 (PubMed Central)
  27. Enterocyte microvillus-derived vesicles detoxify bacterial products and regulate epithelial-microbial interactions. Shifrin DA, McConnell RE, Nambiar R, Higginbotham JN, Coffey RJ, Tyska MJ (2012) Curr Biol 22(7): 627-31
    › Primary publication · 22386311 (PubMed) · PMC3326206 (PubMed Central)
  28. Spasmolytic polypeptide-expressing metaplasia (SPEM) in the gastric oxyntic mucosa does not arise from Lgr5-expressing cells. Nam KT, O'Neal RL, Coffey RJ, Finke PE, Barker N, Goldenring JR (2012) Gut 61(12): 1678-85
    › Primary publication · 22198711 (PubMed) · PMC3767919 (PubMed Central)
  29. Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling. Myers MV, Manning HC, Coffey RJ, Liebler DC (2012) Mol Cell Proteomics 11(2): M111.015222
    › Primary publication · 22147731 (PubMed) · PMC3277773 (PubMed Central)
  30. Proteomic consequences of a single gene mutation in a colorectal cancer model. Halvey PJ, Zhang B, Coffey RJ, Liebler DC, Slebos RJ (2012) J Proteome Res 11(2): 1184-95
    › Primary publication · 22103262 (PubMed) · PMC3271737 (PubMed Central)
  31. Resistance to EGFR-targeted therapy: a family affair. Vlacich G, Coffey RJ (2011) Cancer Cell 20(4): 423-5
    › Primary publication · 22014569 (PubMed) · PMC3616495 (PubMed Central)
  32. Identification of a novel mono-leucine basolateral sorting motif within the cytoplasmic domain of amphiregulin. Gephart JD, Singh B, Higginbotham JN, Franklin JL, Gonzalez A, Fölsch H, Coffey RJ (2011) Traffic 12(12): 1793-804
    › Primary publication · 21917092 (PubMed) · PMC3886124 (PubMed Central)
  33. Adenoma formation following limited ablation of p120-catenin in the mouse intestine. Smalley-Freed WG, Efimov A, Short SP, Jia P, Zhao Z, Washington MK, Robine S, Coffey RJ, Reynolds AB (2011) PLoS One 6(5): e19880
    › Primary publication · 21611205 (PubMed) · PMC3096651 (PubMed Central)
  34. Amphiregulin exosomes increase cancer cell invasion. Higginbotham JN, Demory Beckler M, Gephart JD, Franklin JL, Bogatcheva G, Kremers GJ, Piston DW, Ayers GD, McConnell RE, Tyska MJ, Coffey RJ (2011) Curr Biol 21(9): 779-86
    › Primary publication · 21514161 (PubMed) · PMC3417320 (PubMed Central)
  35. Naked1 antagonizes Wnt signaling by preventing nuclear accumulation of β-catenin. Van Raay TJ, Fortino NJ, Miller BW, Ma H, Lau G, Li C, Franklin JL, Attisano L, Solnica-Krezel L, Coffey RJ (2011) PLoS One 6(4): e18650
    › Primary publication · 21490931 (PubMed) · PMC3072412 (PubMed Central)
  36. Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. Chan E, Lafleur B, Rothenberg ML, Merchant N, Lockhart AC, Trivedi B, Chung CH, Coffey RJ, Berlin JD (2011) Am J Clin Oncol 34(6): 581-6
    › Primary publication · 21217396 (PubMed) · PMC3133812 (PubMed Central)
  37. Distinguishing Ménétrier's disease from its mimics. Rich A, Toro TZ, Tanksley J, Fiske WH, Lind CD, Ayers GD, Piessevaux H, Washington MK, Coffey RJ (2010) Gut 59(12): 1617-24
    › Primary publication · 20926644 (PubMed) · PMC3020399 (PubMed Central)
  38. EGF receptor-independent action of TGF-alpha protects Naked2 from AO7-mediated ubiquitylation and proteasomal degradation. Ding W, Li C, Hu T, Graves-Deal R, Fotia AB, Weissman AM, Coffey RJ (2008) Proc Natl Acad Sci U S A 105(36): 13433-8
    › Primary publication · 18757723 (PubMed) · PMC2527346 (PubMed Central)
  39. Ras-mediated suppression of TGFbetaRII expression in intestinal epithelial cells involves Raf-independent signaling. Bulus NM, Sheng HM, Sizemore N, Oldham SM, Barnett JV, Coffey RJ, Beauchamp DR, Barnard JA (2000) Neoplasia 2(4): 357-64
    › Primary publication · 11005570 (PubMed) · PMC1550294 (PubMed Central)
  40. K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells. Song SY, Meszoely IM, Coffey RJ, Pietenpol JA, Leach SD (2000) Neoplasia 2(3): 261-72
    › Primary publication · 10935512 (PubMed) · PMC1507570 (PubMed Central)
  41. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice. Lenferink AE, Simpson JF, Shawver LK, Coffey RJ, Forbes JT, Arteaga CL (2000) Proc Natl Acad Sci U S A 97(17): 9609-14
    › Primary publication · 10931950 (PubMed) · PMC16912 (PubMed Central)
  42. Crk-associated substrate p130(Cas) interacts with nephrocystin and both proteins localize to cell-cell contacts of polarized epithelial cells. Donaldson JC, Dempsey PJ, Reddy S, Bouton AH, Coffey RJ, Hanks SK (2000) Exp Cell Res 256(1): 168-78
    › Primary publication · 10739664 (PubMed)
  43. Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor alpha. Song SY, Gannon M, Washington MK, Scoggins CR, Meszoely IM, Goldenring JR, Marino CR, Sandgren EP, Coffey RJ, Wright CV, Leach SD (1999) Gastroenterology 117(6): 1416-26
    › Primary publication · 10579983 (PubMed)
  44. Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factor-related peptides. Sizemore N, Cox AD, Barnard JA, Oldham SM, Reynolds ER, Der CJ, Coffey RJ (1999) Gastroenterology 117(3): 567-76
    › Primary publication · 10464132 (PubMed)
  45. Prostaglandin J2 and 15-deoxy-delta12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Chinery R, Coffey RJ, Graves-Deal R, Kirkland SC, Sanchez SC, Zackert WE, Oates JA, Morrow JD (1999) Cancer Res 59(11): 2739-46
    › Primary publication · 10364000 (PubMed)
  46. Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis. Damstrup L, Kuwada SK, Dempsey PJ, Brown CL, Hawkey CJ, Poulsen HS, Wiley HS, Coffey RJ (1999) Br J Cancer 80(7): 1012-9
    › Primary publication · 10362109 (PubMed) · PMC2363033 (PubMed Central)
  47. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Nørgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, Poulsen HS, Moses HL (1999) Clin Cancer Res 5(1): 35-42
    › Primary publication · 9918200 (PubMed)
  48. Identification of rCop-1, a new member of the CCN protein family, as a negative regulator for cell transformation. Zhang R, Averboukh L, Zhu W, Zhang H, Jo H, Dempsey PJ, Coffey RJ, Pardee AB, Liang P (1998) Mol Cell Biol 18(10): 6131-41
    › Primary publication · 9742130 (PubMed) · PMC109199 (PubMed Central)
  49. Increased intestinal epithelial proliferation in metallothioneine-transforming growth factor alpha transgenic mice. Acra SA, Bulus N, Bogatcheva G, Coffey RJ, Barnard JA (1998) Regul Pept 74(2-3): 105-12
    › Primary publication · 9712170 (PubMed)
  50. Cell surface ectodomain cleavage of human amphiregulin precursor is sensitive to a metalloprotease inhibitor. Release of a predominant N-glycosylated 43-kDa soluble form. Brown CL, Meise KS, Plowman GD, Coffey RJ, Dempsey PJ (1998) J Biol Chem 273(27): 17258-68
    › Primary publication · 9642297 (PubMed)
  51. Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells. Chinery R, Beauchamp RD, Shyr Y, Kirkland SC, Coffey RJ, Morrow JD (1998) Cancer Res 58(11): 2323-7
    › Primary publication · 9622066 (PubMed)
  52. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Sheng GG, Shao J, Sheng H, Hooton EB, Isakson PC, Morrow JD, Coffey RJ, DuBois RN, Beauchamp RD (1997) Gastroenterology 113(6): 1883-91
    › Primary publication · 9394727 (PubMed)
  53. Antioxidant-induced nuclear translocation of CCAAT/enhancer-binding protein beta. A critical role for protein kinase A-mediated phosphorylation of Ser299. Chinery R, Brockman JA, Dransfield DT, Coffey RJ (1997) J Biol Chem 272(48): 30356-61
    › Primary publication · 9374525 (PubMed)
  54. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD, Coffey RJ (1997) Nat Med 3(11): 1233-41
    › Primary publication · 9359698 (PubMed)
  55. Apical enrichment of human EGF precursor in Madin-Darby canine kidney cells involves preferential basolateral ectodomain cleavage sensitive to a metalloprotease inhibitor. Dempsey PJ, Meise KS, Yoshitake Y, Nishikawa K, Coffey RJ (1997) J Cell Biol 138(4): 747-58
    › Primary publication · 9265643 (PubMed) · PMC2138042 (PubMed Central)
  56. A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. Gangarosa LM, Sizemore N, Graves-Deal R, Oldham SM, Der CJ, Coffey RJ (1997) J Biol Chem 272(30): 18926-31
    › Primary publication · 9228072 (PubMed)
  57. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN (1997) J Clin Invest 99(9): 2254-9
    › Primary publication · 9151799 (PubMed) · PMC508057 (PubMed Central)
  58. Mob-1, a Ras target gene, is overexpressed in colorectal cancer. Zhang R, Zhang H, Zhu W, Pardee AB, Coffey RJ, Liang P (1997) Oncogene 14(13): 1607-10
    › Primary publication · 9129152 (PubMed)
  59. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, Chinery R, Kirkland SC, DuBois RN, Jetton TL, Morrow JD (1997) Proc Natl Acad Sci U S A 94(2): 657-62
    › Primary publication · 9012840 (PubMed) · PMC19569 (PubMed Central)
  60. Trefoil peptides: less clandestine in the intestine. Chinery R, Coffey RJ (1996) Science 274(5285): 204
    › Primary publication · 8927980 (PubMed)
  61. Roles for transforming growth factor-alpha in the stomach. Coffey RJ, Romano M, Goldenring J (1995) J Clin Gastroenterol : S36-9
    › Primary publication · 8774988 (PubMed)
  62. Transforming growth factor-alpha. Gangarosa LM, Dempsey PJ, Damstrup L, Barnard JA, Coffey RJ (1996) Baillieres Clin Gastroenterol 10(1): 49-63
    › Primary publication · 8732300 (PubMed)
  63. Increased gastroduodenal concentrations of transforming growth factor alpha in adaptation to aspirin in monkeys and rats. Romano M, Lesch CA, Meise KS, Veljaca M, Sanchez B, Kraus ER, Boland CR, Guglietta A, Coffey RJ (1996) Gastroenterology 110(5): 1448-55
    › Primary publication · 8613050 (PubMed)
  64. Basic actions of transforming growth factor-alpha and related peptides. Coffey RJ, Gangarosa LM, Damstrup L, Dempsey PJ (1995) Eur J Gastroenterol Hepatol 7(10): 923-7
    › Primary publication · 8590135 (PubMed)
  65. Transforming growth factor-alpha (TGF alpha) concentrations increase in regenerating rat liver: evidence for a delayed accumulation of mature TGF alpha. Russell WE, Dempsey PJ, Sitaric S, Peck AJ, Coffey RJ (1993) Endocrinology 133(4): 1731-8
    › Primary publication · 8404616 (PubMed)
  66. Chronic administration of transforming growth factor-beta suppresses erythropoietin-dependent erythropoiesis and induces tumour necrosis factor in vivo. Chuncharunee S, Carter CD, Studtmann KE, Caro J, Coffey RJ, Dessypris EN (1993) Br J Haematol 84(3): 374-80
    › Primary publication · 8217788 (PubMed)
  67. Basolateral targeting and efficient consumption of transforming growth factor-alpha when expressed in Madin-Darby canine kidney cells. Dempsey PJ, Coffey RJ (1994) J Biol Chem 269(24): 16878-89
    › Primary publication · 8207010 (PubMed)
  68. Acceleration of mammary neoplasia in transforming growth factor alpha transgenic mice by 7,12-dimethylbenzanthracene. Coffey RJ, Meise KS, Matsui Y, Hogan BL, Dempsey PJ, Halter SA (1994) Cancer Res 54(7): 1678-83
    › Primary publication · 8137281 (PubMed)
  69. Auto- and cross-induction within the mammalian epidermal growth factor-related peptide family. Barnard JA, Graves-Deal R, Pittelkow MR, DuBois R, Cook P, Ramsey GW, Bishop PR, Damstrup L, Coffey RJ (1994) J Biol Chem 269(36): 22817-22
    › Primary publication · 8077234 (PubMed)
  70. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Gastroenterology 107(4): 1183-8
    › Primary publication · 7926468 (PubMed)
  71. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Witty JP, Lempka T, Coffey RJ, Matrisian LM (1995) Cancer Res 55(7): 1401-6
    › Primary publication · 7882342 (PubMed)
  72. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Barnard JA, Beauchamp RD, Russell WE, Dubois RN, Coffey RJ (1995) Gastroenterology 108(2): 564-80
    › Primary publication · 7835600 (PubMed)
  73. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Pierce DF, Gorska AE, Chytil A, Meise KS, Page DL, Coffey RJ, Moses HL (1995) Proc Natl Acad Sci U S A 92(10): 4254-8
    › Primary publication · 7753792 (PubMed) · PMC41922 (PubMed Central)
  74. Transforming growth factor alpha regulation of two zinc finger-containing immediate early response genes in intestine. DuBois RN, Bishop PR, Graves-Deal R, Coffey RJ (1995) Cell Growth Differ 6(5): 523-9
    › Primary publication · 7647035 (PubMed)
  75. Induction of heparin-binding epidermal growth factor-like growth factor mRNA in rat kidney after acute injury. Homma T, Sakai M, Cheng HF, Yasuda T, Coffey RJ, Harris RC (1995) J Clin Invest 96(2): 1018-25
    › Primary publication · 7635938 (PubMed) · PMC185290 (PubMed Central)
  76. Transforming growth factors and control of neoplastic cell growth. Keski-Oja J, Leof EB, Lyons RM, Coffey RJ, Moses HL (1987) J Cell Biochem 33(2): 95-107
    › Primary publication · 3553215 (PubMed)
  77. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. Coffey RJ, Leof EB, Shipley GD, Moses HL (1987) J Cell Physiol 132(1): 143-8
    › Primary publication · 3496343 (PubMed)
  78. Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion. Coffey RJ, Kost LJ, Lyons RM, Moses HL, LaRusso NF (1987) J Clin Invest 80(3): 750-7
    › Primary publication · 3476497 (PubMed) · PMC442299 (PubMed Central)
  79. Predictors of survival after curative resection of carcinoma of the colon and rectum. Griffin MR, Bergstralh EJ, Coffey RJ, Beart RW, Melton LJ (1987) Cancer 60(9): 2318-24
    › Primary publication · 3440238 (PubMed)
  80. Transforming growth factor beta regulation of cell proliferation. Moses HL, Coffey RJ, Leof EB, Lyons RM, Keski-Oja J (1987) J Cell Physiol Suppl : 1-7
    › Primary publication · 3316252 (PubMed)
  81. Regulation of ovarian cell growth through the local production of transforming growth factor-alpha by theca cells. Skinner MK, Coffey RJ (1988) Endocrinology 123(6): 2632-8
    › Primary publication · 3264238 (PubMed)
  82. A new type of transforming growth factor-beta, TGF-beta 3. Derynck R, Lindquist PB, Lee A, Wen D, Tamm J, Graycar JL, Rhee L, Mason AJ, Miller DA, Coffey RJ (1988) EMBO J 7(12): 3737-43
    › Primary publication · 3208746 (PubMed) · PMC454948 (PubMed Central)
  83. Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Russell WE, Coffey RJ, Ouellette AJ, Moses HL (1988) Proc Natl Acad Sci U S A 85(14): 5126-30
    › Primary publication · 3164865 (PubMed) · PMC281701 (PubMed Central)
  84. Transforming growth factor alpha and beta expression in human colon cancer lines: implications for an autocrine model. Coffey RJ, Goustin AS, Soderquist AM, Shipley GD, Wolfshohl J, Carpenter G, Moses HL (1987) Cancer Res 47(17): 4590-4
    › Primary publication · 2887281 (PubMed)
  85. Localization of transforming growth factor alpha and its receptor in gastric mucosal cells. Implications for a regulatory role in acid secretion and mucosal renewal. Beauchamp RD, Barnard JA, McCutchen CM, Cherner JA, Coffey RJ (1989) J Clin Invest 84(3): 1017-23
    › Primary publication · 2760208 (PubMed) · PMC329750 (PubMed Central)
  86. Regulation of epithelial cell proliferation by transforming growth factors. Bascom CC, Sipes NJ, Coffey RJ, Moses HL (1989) J Cell Biochem 39(1): 25-32
    › Primary publication · 2654145 (PubMed)
  87. Complex regulation of transforming growth factor beta 1, beta 2, and beta 3 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors beta 1 and beta 2. Bascom CC, Wolfshohl JR, Coffey RJ, Madisen L, Webb NR, Purchio AR, Derynck R, Moses HL (1989) Mol Cell Biol 9(12): 5508-15
    › Primary publication · 2586525 (PubMed) · PMC363721 (PubMed Central)
  88. Keratinocytes produce and are regulated by transforming growth factors. Pittelkow MR, Coffey RJ, Moses HJ (1988) Ann N Y Acad Sci : 211-24
    › Primary publication · 2470296 (PubMed)
  89. Regulation of intestinal epithelial cell growth by transforming growth factor type beta. Barnard JA, Beauchamp RD, Coffey RJ, Moses HL (1989) Proc Natl Acad Sci U S A 86(5): 1578-82
    › Primary publication · 2466294 (PubMed) · PMC286741 (PubMed Central)
  90. Transforming growth factor-alpha gene expression and action in the seminiferous tubule: peritubular cell-Sertoli cell interactions. Skinner MK, Takacs K, Coffey RJ (1989) Endocrinology 124(2): 845-54
    › Primary publication · 2463904 (PubMed)
  91. Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta. Coffey RJ, Bascom CC, Sipes NJ, Graves-Deal R, Weissman BE, Moses HL (1988) Mol Cell Biol 8(8): 3088-93
    › Primary publication · 2463471 (PubMed) · PMC363535 (PubMed Central)
  92. Growth modulation of mouse keratinocytes by transforming growth factors. Coffey RJ, Sipes NJ, Bascom CC, Graves-Deal R, Pennington CY, Weissman BE, Moses HL (1988) Cancer Res 48(6): 1596-602
    › Primary publication · 2449957 (PubMed)
  93. Production and auto-induction of transforming growth factor-alpha in human keratinocytes. Coffey RJ, Derynck R, Wilcox JN, Bringman TS, Goustin AS, Moses HL, Pittelkow MR (1987) Nature 328(6133): 817-20
    › Primary publication · 2442615 (PubMed)
  94. Expression of and response to growth regulatory peptides by two human pancreatic carcinoma cell lines. Beauchamp RD, Lyons RM, Yang EY, Coffey RJ, Moses HL (1990) Pancreas 5(4): 369-80
    › Primary publication · 2199964 (PubMed)
  95. Pharmacokinetics of TGF beta with emphasis on effects in liver and gut. Coffey RJ, Russell WE, Barnard JA (1990) Ann N Y Acad Sci : 285-91
    › Primary publication · 2197961 (PubMed)
  96. Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta. Arteaga CL, Coffey RJ, Dugger TC, McCutchen CM, Moses HL, Lyons RM (1990) Cell Growth Differ 1(8): 367-74
    › Primary publication · 2177634 (PubMed)
  97. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Matsui Y, Halter SA, Holt JT, Hogan BL, Coffey RJ (1990) Cell 61(6): 1147-55
    › Primary publication · 2161707 (PubMed)
  98. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. McDonnell S, Navre M, Coffey RJ, Matrisian LM (1991) Mol Carcinog 4(6): 527-33
    › Primary publication · 1793490 (PubMed)
  99. Production of transforming growth factor-alpha by normal rat small intestine. Barnard JA, Polk WH, Moses HL, Coffey RJ (1991) Am J Physiol 261(6 Pt 1): C994-1000
    › Primary publication · 1767826 (PubMed)
  100. Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G, Page DL (1991) Proc Natl Acad Sci U S A 88(23): 10435-9
    › Primary publication · 1683701 (PubMed) · PMC52943 (PubMed Central)
  101. Increased production of transforming growth factor alpha following acute gastric injury. Polk WH, Dempsey PJ, Russell WE, Brown PI, Beauchamp RD, Barnard JA, Coffey RJ (1992) Gastroenterology 102(5): 1467-74
    › Primary publication · 1568557 (PubMed)
  102. Differential regulation of transforming growth factor alpha autoinduction in a nontransformed and transformed epithelial cell. Coffey RJ, Graves-Deal R, Dempsey PJ, Whitehead RH, Pittelkow MR (1992) Cell Growth Differ 3(6): 347-54
    › Primary publication · 1419897 (PubMed)
  103. Roles for transforming growth factor-alpha in gastric physiology and pathophysiology. Coffey RJ, Romano M, Polk WH, Dempsey PJ (1992) Yale J Biol Med 65(6): 693-704; discussion 621-3
    › Primary publication · 1341072 (PubMed) · PMC2589761 (PubMed Central)
  104. Transforming growth factors and related peptides in gastrointestinal neoplasia. Coffey RJ, McCutchen CM, Graves-Deal R, Polk WH (1992) J Cell Biochem Suppl : 111-8
    › Primary publication · 1335097 (PubMed)
  105. Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-alpha. Characterization of mammary gland and skin proliferations. Halter SA, Dempsey P, Matsui Y, Stokes MK, Graves-Deal R, Hogan BL, Coffey RJ (1992) Am J Pathol 140(5): 1131-46
    › Primary publication · 1316084 (PubMed) · PMC1886506 (PubMed Central)
  106. Transforming growth factor alpha protection against drug-induced injury to the rat gastric mucosa in vivo. Romano M, Polk WH, Awad JA, Arteaga CL, Nanney LB, Wargovich MJ, Kraus ER, Boland CR, Coffey RJ (1992) J Clin Invest 90(6): 2409-21
    › Primary publication · 1281834 (PubMed) · PMC443397 (PubMed Central)